Figure 4.
Figure 4. DAP12-deficient IPCs do not express NKp44. (A) To confirm DAP12 deficiency, we evaluated granulocytes for expression of TREM-1, a DAP12-associated receptor (right). TREM-1 expression was determined by gating on CD16+ side scatter (SSC) high granulocytes (left). (B) The presence of IPCs in DAP12-deficient PBMCs was confirmed by analyzing PBMCs for expression of BDCA-2 and CD123. Lineage-positive cells (CD3+, CD14+, CD16+, CD20+, CD56+) were excluded from the analysis. (C) Total PBMCs from a healthy donor and the DAP12-deficient patient were cultured overnight in the presence (right) or absence (left) of IL-3. Selective expression of NKp44 on IPCs was evaluated by counterstaining with BDCA-2. CD19+, CD14+, and CD56+ cells were excluded from the analysis.

DAP12-deficient IPCs do not express NKp44. (A) To confirm DAP12 deficiency, we evaluated granulocytes for expression of TREM-1, a DAP12-associated receptor (right). TREM-1 expression was determined by gating on CD16+ side scatter (SSC) high granulocytes (left). (B) The presence of IPCs in DAP12-deficient PBMCs was confirmed by analyzing PBMCs for expression of BDCA-2 and CD123. Lineage-positive cells (CD3+, CD14+, CD16+, CD20+, CD56+) were excluded from the analysis. (C) Total PBMCs from a healthy donor and the DAP12-deficient patient were cultured overnight in the presence (right) or absence (left) of IL-3. Selective expression of NKp44 on IPCs was evaluated by counterstaining with BDCA-2. CD19+, CD14+, and CD56+ cells were excluded from the analysis.

Close Modal

or Create an Account

Close Modal
Close Modal